Last reviewed · How we verify
Trusopt (DORZOLAMIDE)
Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye.
Trusopt (Dorzolamide) is a small molecule carbonic anhydrase inhibitor developed by Merck and currently owned by MSD Subsidiary of Merck. It targets carbonic anhydrase 2 to treat ocular hypertension and open-angle glaucoma. Trusopt is a generic medication with no active Orange Book patents, making it widely available. As a carbonic anhydrase inhibitor, it works by reducing the production of aqueous humor in the eye, thereby lowering intraocular pressure. It is an effective treatment option for patients with glaucoma or ocular hypertension.
At a glance
| Generic name | DORZOLAMIDE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Carbonic Anhydrase Inhibitor |
| Target | Carbonic anhydrase 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1994 |
Mechanism of action
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is reduction in intraocular pressure (IOP).TRUSOPT contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II. Following topical ocular administration, TRUSOPT reduces elevated intraocular pressure. Elevated intraocular pressure is major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- dizziness
- ocular pain
- transient myopia
- choroidal detachment following filtration surgery
- eyelid crusting
- dyspnea
- contact dermatitis
- epistaxis
- dry mouth
- throat irritation
- angioedema
- bronchospasm
Key clinical trials
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trusopt CI brief — competitive landscape report
- Trusopt updates RSS · CI watch RSS
- Merck & Co. portfolio CI